Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SHANGHAI and HONG KONG, July 25, 2021 /PRNewswire/ In June 2021, results from a preclinical study jointly conducted by Antengene, American biopharmaceutical company Karyopharm Therapeutics and University of Georgia College of Veterinary Medicine has been published in a paper titled
selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo , in
Antiviral Research (192(2021)，105-115), a leading scientific journal in the field of virology. Results from the study showed that the nuclear export protein exportin-1 (XPO1) plays a direct role in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the pathogenesis of coronavirus disease 19 (COVID-19); and the selective oral inhibitor of XPO1, selinexor, has potent anti-SARS-CoV-2 activity both in vitro and in vivo. These results demonstrated selinexor as a potential therapeutic strategy for COVID-19
International hospital accreditation skyrockets 1,000%
August 18, 2009
In the last five years, the number of JCI (Joint Commission International) accredited public and private hospitals around the world has increased by nearly 1,000 percent.
In the last five years, the number of JCI (Joint Commission International) accredited public and private hospitals around the world has increased by nearly 1,000 percent. Up from a mere 27 hospitals and health care organizations with that accreditation in 2004, currently over 250 such entities in 36 countries have now been accredited by the JCI. This extremely high standard of “American accreditation” now instills a new level of confidence in US citizens seeking affordable health care alternatives abroad. With the US Congress currently locked in a fierce battle over how to solve the national health care crisis, Josef Woodman, author of Patients Beyond Borders, joins Sandy Dhuyvetter on TravelTalkRADIO to discuss this extraordinarily releva
Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies
-In July 2019, selinexor (XPOVIO®) was approved by the U.S. FDA and became the first and only XPO1 inhibitor indicated for the treatment of hematologic malignancies.
-Selinexor has been approved in the U.S., Israel, UK, and EU countries.
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, July 13, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for selinexor, a first-in-class XPO1 inhibitor, for three indications: in combination with bortezomib and dexamethasone (XVd), or in combination w
vimarsana © 2020. All Rights Reserved.